Ohio State Navbar

Directory

Samantha Jaglowski, MD


Staff photo

320 W 10th Ave
A354 Starling Loving Hall
Columbus, OH 43210

Phone: (614) 293-2268

Email: jaglowski.1@osu.edu

 

Current OSU Appointments

Assistant Professor-Clinical, Hematology

Physician, FGP-Hematology

 

Clinical Interest

Hematology

Biographical

1. Candidate background

I earned my B.S. in zoology at the Ohio State University, graduating summa cum laude with honors in the Liberal Arts and Distinction in Zoology; my honors project evaluated the ability of ɣ-tocopheryl quinine to induce apoptosis in a HeLa cervical carcinoma cell line. I remained at Ohio State for medical school and decided to stay for internal medicine residency primarily because of the program’s emphasis on excellent resident education. During residency, I met Dr. John Byrd and became interested in chronic lymphocytic leukemia (CLL) and the immune defects inherent in the disease. I also gave birth to three daughters who taught me about priorities.

I remained at Ohio State for a medical oncology fellowship with the intent of joining Dr. Byrd’s lab as a T32 fellow. Shortly after beginning my fellowship, I was diagnosed with a tumor invading my brainstem and learned all too well what it is like to be a cancer patient, given the choice between substantial morbidity with the possibility of a cure or preserved function with almost certain death, particularly given my age and the lack of chemotherapeutic options. My tumor was resected with curative intent, and I was fortunate to be allowed to return to work 6 months after my diagnosis, still undergoing extensive rehabilitation; my interest shifted toward late effects and survivorship research as well as early phase clinical trial design as a result. To that end, I enrolled in Ohio State’s College of Public Health, graduating with a Master’s in Public Health (MPH) in August 2012. Upon completing my medical oncology fellowship, I pursued an additional year of training in stem cell transplantation under the direction of Dr. Steven Devine, in part out of a desire to harness the immune system to be able to offer patients a potentially curative therapy in an area where chemotherapy so frequently fails. This cure often comes with a price, however, and my research focus is evaluating methods to mitigate or abrogate the potentially devastating effects of graft-versus-host disease (GVHD) and other complications of transplant, including novel targeted therapeutics.

I remained on the faculty at The Ohio State University, becoming a tenure track Assistant Professor of Internal Medicine in the Division of Hematology in October 2011, where my clinical foci are stem cell transplantation in patients with lymphoid malignancies and late effects of transplant. I have been fortunate to be awarded a position on Ohio State’s K12. Ohio State has a record for successful mentorship with several recent K23 awards within the malignant hematology group, as well as outstanding mentorship available from Drs. Byrd and Devine, as well as Michael Caligiuri and Michael Grever.

2. Scientific biography

During my medical oncology fellowship, I presented 2 first author abstracts at the 2009 ASH Annual Meeting, a first author abstract at the 2010 ASBMT Annual Meeting, and a manuscript stemming from these abstracts was recently published. I was the first author of 3 review articles, including an article on the clinical application of monoclonal antibodies which appeared in the journal Blood. During my transplant fellowship, I performed a retrospective review of institutional outcomes data following reduced-intensity allograft for CLL, specifically looking at the role of interphase and metaphase cytogenetics; an abstract for this was presented at the 2011 ASH Annual Meeting and a manuscript was published in the British Journal of Haematology. Much of the time at the end of my medical oncology fellowship and during transplant fellowship was dedicated to developing a protocol combining ibrutinib (formerly PCI-32765) and ofatumumab for patients with relapsed or refractory CLL/SLL and related diseases such as PLL and Richter’s transformation. I received the Conquer Cancer Foundation Young Investigator Award and the ASH Scholar Award for this project and presented preliminary results from the first cohort as an oral presentation at the 2012 ASCO Annual Meeting. A manuscript is in active preparation and will be submitted to Lancet Oncology.

Since becoming an assistant professor, my clinical and research interests have been more heavily focused on transplant. I performed a retrospective review of our institutional outcomes following autologous transplant for lymphoma and multiple myeloma with a focus on identifying risk factors for morbidity including early readmission following transplant. This data was presented at the 2012 ASH Annual Meeting and a manuscript has been published in Bone Marrow Transplantation. Based on the results of this study, I am performing a prospective study of a comprehensive functional assessment tool including frailty biomarkers to attempt to identify a cohort of patients who would benefit from aggressive intervention while inpatient or closer follow up after discharge to prevent excess morbidity.

Over the past year, I have been developing a Chronic Graft-Versus-Host Disease clinic at Ohio State in order to streamline care for long-term survivors of allogeneic transplant, facilitating the recommended evaluations for these patients. This clinic will allow us to perform longitudinal studies of long-term survivors of stem cell transplant, including collecting and banking biologic specimens. Dr. Karen Wood in pulmonology and Dr. Benjamin Kaffenberger in dermatology will be available to see patients in this clinic, and we are working to recruit physicians from other specialties to help improve care for our long-term patients. Ohio State has recently joined the Chronic GVHD Consortium, led by Dr. Stephanie Lee at the Fred Hutchinson Cancer Research Center, and I am serving as our local principal investigator. A large part of this consortium is an R01 study evaluating the natural history of patients with cGVHD and validating response metrics. In addition to having the opportunity to participate in Consortium studies, this gives us access to a wonderful group of collaborators should our initial studies prove interesting. I have designed a phase I study evaluating milatuzumab, an anti-CD74 monoclonal antibody, as prophylaxis for acute GVHD and was awarded an ASBMT New Investigator Award for this project. Additionally, based on a concept for a phase Ib/II study of ibrutinib in steroid-refractory chronic GVHD, I was invited to participate in the ASBMT Clinical Research Training Course. This concept has evolved into a multi-center clinical trial and I am the co-protocol director along with Dr. David Miklos at Stanford.

Academic Advising

2013 - present Brad Haverkos, The Ohio State University. Graduated 2008.
2014 - present Marcello Rotta, The Ohio State University. Graduated 2002.
2014 , The Ohio State University.
 

Licenses

2009 - present Board Certification: American Board of Internal Medicine
2010 - present Medical License: State Medical Board of Ohio
2011 - present Board Certification: American Board of Internal Medicine
 

Clinical Services

01/01/2011 Inpatient Hematology 1 (HEM 1) Service (James Cancer Hospital, Internal Medicine, Division of Hematology)
04/01/2011 Inpatient Hematology 3 (HEM 3) Service (James Cancer Hospital, Internal Medicine/Division of Hematology)
11/01/2011 Outpatient Hematopoietic Cell Transplant Clinic (James Cancer Hospital, Internal Medicine, Division of Hematology)
12/01/2011 Inpatient Bone Marrow Transplant (BMT) Service (James Cancer Hospital, Internal Medicine, Division of Hematology)

Conferences

Jaglowski SM, Lin TL, Elder P, Scholl D, Byrd JC, Devine SM, Andritsos LA.. "Barriers to Reduced-Intensity Conditioning (RIC) Transplant in Patients with Chronic Lymphocytic Leukemia." In BLOOD. (November 2009). 559-560.

Jaglowski SM, Byrd JC, Jones JA. "In-Hospital Mortality and Trends Associated with Splenectomy in Patients with Immune-Mediated Thrombocytopenia (ITP).." In BLOOD. (November 2009). Abstract #1374-.

Jaglowski SM, Flynn JM, Jones JA, Lin TS, Fischer B, Scholl D, Elder P, Devine SM, Grever MR, Byrd JC, Andritsos LA.. "Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant." In BLOOD. (November 2010). 987-988.

Herman SEM, Gordon AL, Mahoney E, Jaglowski SM, Blum KA, Buggy J, Hamdy A, Byrd JC, Johnson AJ. "The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals." In BLOOD. (November 2010). 596-596.

Jaglowski SM, Heerema N, Elder P, Scholl D, Hamadani M, Byrd JC, Devine SM, Andritsos LA. "Complex Karyotype Predicts Poor Response to Salvage Therapy and Ineligibility for Reduced Intensity Conditioning Transplantation in CLL." In Biology of Blood and Marrow Transplantation. (February 2010). Abstract #335-.

Jaglowski SM, Heerema NA, Elder P, Byrd JC, Devine SM, Andritsos LA. "Increasing Genetic Complexity Predicts for Inferior Outcomes Following Reduced-Intensity Conditioning Allogeneic Transplant for Chronic Lymphocytic Leukemia." In BLOOD. (November 2011). 1335-1335.

Jaglowski SM, Hofmeister CC, Elder P, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA. "The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma." In BLOOD. (November 2012). Abstract #4286-.

Hamadani M, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston A, Bunner P, Basu S, Tse W, Hennelly C, Vasu S, Klisovic RB, Blum W, Jaglowski SM, Benson DM, Andritsos LA, Penza S, Hofmeister CC, Geyer S, Devine SM, Efebera YA. "Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)." In BLOOD. (November 2012). abstract #1942-.

Jaglowski SM, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Andritsos LA, Lozanski G. "Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease." In BLOOD. (November 2012). Abstract #1949-.

Vasu S, Jaglowski SM, Geyer S, Bingman A, Elder P, Yu J, Andritsos LA, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Lozanski G. "Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)." In BLOOD. (November 2012). Abstract 4192-.

Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Blum KA, Grever MR, Geyer S, Woyach JA, Johnson AJ, Heerema NA, Molnar E, Stefanos M, Devlin S, Navarro T, James D, Lowe A, Hedrick E, Byrd JC.. "A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.." In JOURNAL OF CLINICAL ONCOLOGY. (May 2012). Abstract #6508-.

Yu J, He S, Wu L, Mao H, Vasu S, Jaglowski SM, Peng Y, Alvarez-Breckenridge C, Yuan S, Wei M, Zhang J, Hughes TL, Ghoshal K, Devine SM, Caligiuri MA.. "Micrornas Promote Activation and Maturation of Natural Killer Cells Through Toll-Like Receptor Signaling.." In BLOOD. (November 2012). Abstract #2160-.

Dubovsky JA, Beckwith KA, Woyach JA, Jaglowski SM, Hessler J, Chang BY, Larkin K, Stefanovski MR, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman A, Furman RR, Sharman J, Mishra A, Caligiuri MA, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. "Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells." In BLOOD. (November 2012). Abstract #775-.

Blum KA, Christian B, Flynn JM, Jaglowski SM, Jones JA, Maddocks KJ, Byrd JC. "A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)." In BLOOD. (November 2012). Abstract #1643-.

Efebera Y, Geyer S, Bingman A, Kitzler R, Elder P, Hennelly C, Andritsos LA, Jaglowski SM, Blum W, Klisovic RB, Penza S, Vasu S, Hofmeister CC, Benson DM, Devine SM, Lozanski G. "Impact of Atorvastatin On Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S202-S202.

Salem S, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic RB, Vasu S, Blum W, Devine SM, Jaglowski SM, Efebera YA. "Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S304-S305.

Stephens DM, Ruppert AS, Jones J, Woyach J, Maddocks K, Jaglowski S, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. "Changing the treatment paradigm for previously treated chronic lymphocytic leukemia patients with del(17p) karyotype." In BLOOD. (November 2013). Abstract #2872-.

Stephens D, Ruppert AS, Wierda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam CS, O’Brien S, Keating MJ, Muthusamy R, Abruzzo LV, Heerema NA, Byrd JC. "Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients." In BLOOD. (November 2013). Abstract #4128-.

Pandit A, Wei L, Elder P, Falk W, Sell M, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R, Vasu S, Blum W, Devine SM, JaglowskiSM, Efebera YA. "Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis)." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2013). S186-S186.

El-Jawahri A, Pidala J, Chai X, Wood WA, Khera N, Arora M, Jaglowski SM, Lee SJ, Chen Y. "Do older patients with moderate-severe chronic graft-versus-host disease differ from younger patients?." In BLOOD. (November 2013). Abstract #725-.

McBride A, Geyer S, Jaglowski S, Devine SM, Andritsos LA.. "Plerixafor Mobilization in MM Patients and Impact on CD34 Cell Collection and Transplant Outcomes." In Biology of Blood and Marrow Transplantation. (February 2014). S293-.

El-Jawahri A, Pidala J, Chai X, Wood WA, Khera N, Arora M, Jaglowski S, Lee SJ, Chen Y. "The Impact of Age on Quality of Life, Functional Status, and Overall Survival in Patients with Moderate-Severe Chronic Graft-versus-Host Disease." In Biology of Blood and Marrow Transplantation. (February 2014). S65-S65.

Haverkos BM, Geyer S, McBride A, Penza S, Devine SM, Andritsos LA, Jaglowski S. "Mobilization for Autologous Stem Cell Transplantation in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma: A Single Institution Experience." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2014). S111-S112.

Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Geyer SM, Heerema NA, Lozanski G, Stefanos M, Hall N, Nagar V, Munneke B, West J, Neuenburg J, James DF, Johnson AJ, Byrd JC.. "A Phase 1b/2 Study Evaluating Activity and Tolerability of the BTK Inhibitor Ibrutinib in Combination with Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Related Diseases.." In Journal of Clinical Oncology. (May 2014). 32:52 Abstract #7009-.

Woyach JA, Ruppert AS, Lozanski G, Lozanski A, Heerema NA, Zhao W, Abruzzo L, Gordon A, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Maddocks KJ. "Association of Disease Progression on Ibrutinib Therapy with the Acquisition of Resistance Mutations: A Single-Center Experience of 267 Patients." In Journal of Clinical Oncology. (May 2014). Abstract #7010-.

Issa,Hassan; Ruppert,Amy,S; Elder,Patrick; Hofmeister,Craig; Benson,Don,M; Penza,Sam; Andritsos,Leslie,A; Klisovic,Rebecca,B; Vasu,Sumithira; Blum,William; Jaglowski,Samantha,M; Devine,Steven,M; Efebera,Yvonne,A. "Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)." In BLOOD. (December 2015). .-.

Jaglowski,Samantha,M; Jones,Jeffrey,A; Flynn,Joseph,M; Andritsos,Leslie,A; Maddocks,Kami,J; Woyach,Jennifer,A; Blum,Kristie,A; Greyer,Michael,R; Geyer,Susan,Michelle; Heerema,Nyla,A; Lozanski,Gerard; Stefanos,Mona; Hall,Nathan; Nagar,Veena; Munneke,Brian; West,Jamie-Sue; Neuenburg,Jutta,K; James,Danelle,F; Johnson,Amy,J; Byrd,John,C. "Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)." In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. (June 2015). S206-S207.

 

Degrees

2000 A.A.S., The Ohio State University

2004 B.A., The Ohio State University

2012 B.S.Ch.E., The Ohio State University

 

Editorial Activities

2010 - present Leukemia
2012 - present Expert Review of Hematology
2012 - present Blood
2012 - present Expert Reviews in Anticancer Therapy
2012 Biology of Blood and Marrow Transplantation
2013 - present Personalized Medicine
2013 - present Haematologica
2013 - present Future Medicine
2013 Drugs of the Future
2014 - present New England Journal of Medicine
2014 Current Opinon in Hematology
 

Honors

2000 Phi Beta Kappa. Phi Beta Kappa.
2001 Letter of Commendation in Medical Humanities. The Ohio State University.
2001 Arthritis Foundation Grant. Arthritis Foundation.
2002 Letter of Commendation in Pediatrics. The Ohio State University.
2002 Honors in Psychiatry. The Ohio State University.
2003 Letter of Commendation in Internal Medicine. The Ohio State University.
2003 Honors in Medical Education.
2004 Honors in Gynecology. The Ohio State University.
2004 Honors in Pain/Palliative Care. The Ohio State University.
2010 Outstanding Clinical Care by a Fellow. The Ohio State University College of Medicine.
2011 American Society of Hematology Scholar Award. American Society of Hematology.
2011 JCO Young Investigator Award. American Society of Clinical Oncology.
2012 ASBMT Clinical Research Training Course. American Society of Blood and Marrow Transplantation.
2013 - present NIH Loan Repayment Award. National Institute of Health.
2013 - 2015 ASBMT New Investigator Award. American Society of Blood and Marrow Transplantation.
 

Journal Articles

Jaglowski SM; Linden E; Termuhlen AM; Flynn JM. "Lymphoma in adolescents and young adults.." Seminars In Oncology. Vol. 36, no. 5. (October 2009.): 381-.

Jaglowski SM. "Lovenox hurts.." Annals Of Internal Medicine. Vol. 151, no. 8. (October 2009.): 585-.

Jaglowski SM. "Lovenox hurts.." Annals of Internal Medicine. Vol. 151, no. 8. (October 2009.): 585-586.

Jaglowski SM, Linden E, Termuhlen AM, Flynn JM. "Lymphoma in Adolescents and Young Adults." Seminars in Oncology. Vol. 36, no. 5. (October 2009.): 381-418.

Jaglowski SM; Byrd JC. "Rituximab in chronic lymphocytic leukemia.." Seminars In Hematology. Vol. 47, no. 2. (April 2010.): 156-.

Jaglowski SM, Alinari L, Lapalombella R, Muthusamy R, Byrd JC. "The Clinical Application of Monoclonal Antibodies in CLL." Blood. (November 2010.): 3705-3714.

Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. "The clinical application of monoclonal antibodies in chronic lymphocytic leukemia." Blood. Vol. 116, no. 19. (November 2010.): 3705-3714.

Jaglowski SM, Byrd JC. "Rituximab in Chronic Lymphocytic Leukemia." Seminars in Hematology. Vol. 47, no. 2. (April 2010.): 156-169.

Jaglowski S, Jones JA. "Choosing first-line therapy for chronic lymphocytic leukemia." Expert Review of Anti Cancer Therapy. Vol. 11, no. 9. (September 2011.): 1379-1390.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. "Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765." Blood. Vol. 117, no. 23. (June 2011.): 6287-6296.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC.. "Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765." BLOOD. Vol. 117, no. 23. (November 2011.): 6287-6296.

Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR, Jones Ja, Elder P, Devine SM, Byrd JC, Andritsos LA. "Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.." British journal of haematology. Vol. 159, no. 1. (October 2012.): 82-87.

Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Blum KA, Grever MR, Geyer SM, Woyach JA, Johnson AJ, Heerema NA, Molnar E, Stefanos M, Devlin S, Navarro T, James DF, Lowe AM, Hedrick E, Byrd JC. "A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.." JOURNAL OF CLINICAL ONCOLOGY. Vol. 30, no. 15. (May 2012.): .-.

Jaglowski SM, Byrd JC. "Novel Therapies and Their Integration into Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia." Biology of Blood and Marrow Transplantation. Vol. 18, no. 1. (January 2012.): S132-S138.

Blum KA, Christian BA, Flynn JM, Jaglowski SM, Jones JA, Maddocks KJ, Byrd JC. "A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)." BLOOD. Vol. 120, no. 21. (November 2012.): .-.

Jaglowski SM, Hofmeister CC, Elder P, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA,. "The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma." BLOOD. Vol. 120, no. 21. (November 2012.): 1323-1329.

El Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee SJ, Chen YB. "Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease." Biology of Blood Marrow Transplantation. Vol. 20, no. 9. (September 2014.): 1341-1348.

Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA. "Lower dose of antithymocyte globulin (ATG) does not increase graft-versus-host disease (GVHD) in patients undergoing reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplant (allo-HSCT)." Leuk Lymphoma. Vol. [Epub ahead of print], (August 2014.): .-.

Haverkos B, McBride A, O’Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos L, Devine S, Jaglowski S.. "An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor." Bone Marrow Transplant. Vol. 49, no. 8. (September 2014.): 1052-1055.

Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM, Jaglowski S, Penza S, Andritsos LA, Devine SM. "Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study." Support Care Cancer. Vol. [Epub ahead of print], (May 2014.): .-.

Jaglowski SM, Devine SM. "Graft-versus-host disease: why have we not made more progress?." CURRENT OPINION IN HEMATOLOGY. Vol. 21, no. 2. (March 2014.): 141-147.

Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA.. "The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma." Bone Marrow Transplant. Vol. [Epub ahead of print], (July 2014.): .-.

Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Penza S, Benson DM, Andritsos LA, Devine SM. "A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma." Leuk Lymphoma. Vol. [Epub ahead of print], (September 2014.): .-.

Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, LiDH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC. "Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib." New England Journal of Medicine. Vol. 370, no. 24. (June 2014.): 2286-94.

El Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee SJ, Chen YB. "Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease." Biology of Blood Marrow Transplantation. Vol. 20, no. 9. (September 2014.): 1341-1348.

Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks KJ, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. "Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center." LEUKEMIA. Vol. 28, no. 6. (June 2014.): 1365-1368.

Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA. "The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma." New England Journal of Medicine. Vol. 370, no. 24. (June 2014.): 2286-94.

 

Presentations

"Barriers to Reduced-Intensity Conditioning (RIC) Transplant in Patients with Chronic Lymphocytic Leukemia." Presented at American Society of Hematology Annual Meeting 2009 (ASH), Orlando, FL, US|USA. (December 2009)

"In-Hospital Mortality and Trends Associated with Splenectomy in Patients with Immune-Mediated Thrombocytopenia (ITP)." Presented at American Society of Hematology Annual Meeting 2009 (ASH), Orlando, FL, US|USA. (December 2009)

"Lovenox Hurts." Presented at Annals of Internal Medicine, . (October 2009)

"Lovenox Hurts." Presented at Annals of Internal Medicine Podcast, . (December 2009)

"Flavopiridol is an Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant." Presented at American Society of Hematology Annual Meeting 2010 (ASH), Orlando, FL, US|USA. (December 2010)

"Complex Karyotype Predicts Poor Response to Salvage Therapy and Ineligibility for Reduced Intensity Conditioning Complex Karyotype Predicts Poor Response to Salvage Therapy and Ineligibility for Reduced Intensity Conditioning Transplantation in CLL." Presented at American Society for Blood and Marrow Transplantation Annual Meeting 2010 (ASBMT), Orlando, FL, US|USA. (February 2010)

"Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era: the CORAL Study." Presented at Bone Marrow Transplant Journal Club, Columbus. (May 2011)

"Project Cancer Education." Presented at Project Cancer Education, . (October 2011)

"Leukemia, Myelodysplasia and Pediatric Oncology." Presented at 4th Annual World Cancer Congress, Dalian, CN|CHN. (May 2011)

"Clinical benefit of response in chronic graft-versus-host disease." Presented at Bone Marrow Transplant Journal Club, . (August 2012)

"The hematopoietic stem cell transplant comorbidity index (HCT-CI) can predict for readmission following autologous stem cell transplant for lymphoma and multiple myeloma." Presented at American Society of Hematology Annual Meeting (ASH), Atlanta, GA, US|USA. (December 2012)

"A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases." Presented at American Society of Clinical Oncology Annual Meeting (ASCO), Chicago, IL, US|USA. (June 2012)

"Immune reconstitution at days 30 and 100 following allogeneic stem cell transplant and association with subsequent development of chronic graft-versus-host disease." Presented at American Society of Hematology Annual Meeting (ASH), Atlanta, GA, US|USA. (December 2012)

"Clinical Oncology and Medical Practice." Presented at 5th Annual World Cancer Congress, Beijing, CN|CHN. (May 2012)

"Medical Research on Hematology and Oncology and Endocrine System Tumors." Presented at 6th Annual World Cancer Congress, Hilton Xi'an, CN|CHN. (May 2013)

"Leukemia and Lymphoma of Stream 2: Best Clinical Practice Forum; Best Clinical Practice on Cancer Treatment." Presented at 7th Annual World Cancer Congress, Nanjing, CN|CHN. (May 2014)

 

Unpublished Works

Maddocks K, Christian BA, Jaglowski SM, Flynn J, Jones J, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory lymphoma.. November 2014.

Amin E, Phillips G, Elder P, Jaglowski S, Devine S, Wood K. Health related quality of life in patients that develop bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. November 2014.

Jaglowski SM. Transplant for CLL: Still an option?. October 2014.